SciSparc & Clearmind Patent for Binge Behavior Treatment
Ticker: SPRC · Form: 6-K · Filed: Jan 7, 2025 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Jan 7, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: patent, collaboration, psychedelics, pharmaceuticals
TL;DR
SciSparc and Clearmind just got a European patent application published for a psychedelic combo drug targeting binge behavior. Big win for their pipeline.
AI Summary
On January 6, 2025, SciSparc Ltd. announced a collaboration with Clearmind Medicine regarding the publication of a European patent application. This application covers a psychedelic combination treatment for binge behavior. The patent is related to SciSparc's proprietary drug candidate, SCI-110.
Why It Matters
This patent publication could strengthen SciSparc's intellectual property portfolio and advance its potential treatments for behavioral disorders.
Risk Assessment
Risk Level: medium — The filing concerns a patent application publication, which is a step in the patent process but does not guarantee approval or commercial success.
Key Players & Entities
- SciSparc Ltd. (company) — Registrant
- Clearmind Medicine (company) — Collaborator
- SCI-110 (drug_candidate) — SciSparc's proprietary drug
- January 6, 2025 (date) — Date of press release
FAQ
What is the specific title of the press release issued by SciSparc Ltd. on January 6, 2025?
The press release is titled 'SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment.'
What is the main subject of the European patent application mentioned in the filing?
The European patent application covers a psychedelic combination treatment for binge behavior.
Which company is collaborating with SciSparc Ltd. on this patent application?
Clearmind Medicine is collaborating with SciSparc Ltd.
What is SciSparc's proprietary drug candidate related to this patent?
SciSparc's proprietary drug candidate related to this patent is SCI-110.
Under which rule of the Securities Exchange Act of 1934 is this Form 6-K filed?
This Form 6-K is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Filing Stats: 311 words · 1 min read · ~1 pages · Grade level 11.7 · Accepted 2025-01-07 06:15:30
Filing Documents
- ea0226871-6k_scisparc.htm (6-K) — 12KB
- ea022687102ex99-1_scisparc.htm (EX-99.1) — 7KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-25-001380.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: January 7, 2025 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3